Skip to content

A study to evaluate the safety and efficacy of AspireAssist™ in morbidly obese adolescents

A study to evaluate the safety and efficacy of AspireAssist™ in morbidly obese adolescents: a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN36495438
Enrollment
40
Registered
2016-08-03
Start date
2016-09-01
Completion date
Unknown
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent obesity Nutritional, Metabolic, Endocrine

Interventions

This AspireAssist study is an interventional study with a control. The study is designed as a two-arm study with randomization in the proportion of 20 subjects in the treatment group receiving the As

Sponsors

Vítkovicke Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 16 to 21 years at the time of selection for the study 2. Body mass index (BMI) 35 to 55 kg/ m2 3. Comorbidities such as hypertension and dyslipidemia treated by an appropriate specialist are permissible 4. Ability to comprehend the content of the informed consent form. 5. Cooperation of the subject's parents 6. Non-smoker

Exclusion criteria

Exclusion criteria: 1. BMI below 35 or above 55 2. History of stomach and gallbladder surgeries 3. Previous technical difficulties with gastroduodenoscopy or a failure to carry out an endoscopy 4. Type 1 diabetes 5. Insulin therapy 6. History of gastrointestinal disease (acute gastritis, non-specific colitis) 7. Confirmed celiac disease 8. History of malignity 9. Previous endoscopic and surgical treatment of obesity (intragastric balloons, endoscopic or surgical gastric procedures, malabsorptive procedures of the GIT) 10. Specific genetic or hormonal disorders associated with obesity (Prader-Wili syndrome, MC4R mutation etc.) 11. Coagulation and hemopoiesis disorders 12. Both chronic and acute pancreatitis 13. Psychiatric disorders (endogenous depression, schizophrenia, suicidal tendencies, psychoses) 14. Uncontrolled hypertension (systolic BP > 150 mm Hg or diastolic BP > 100 mm Hg) 15. Autoimmune diseases or long-term use of systemic glucocorticoids or immunosuppressive therapy 16. Thyroid function disorders unresponsive to treatment 17. Kidney function disorders with GFR 1000 mg/day

Design outcomes

Primary

MeasureTime frame
Body weight reduction measured as % Total Body Weight loss will be evaluated at 3, 6 and 12 months of treatment.

Secondary

MeasureTime frame
1. Waist circumference and BMI changes 2. Body composition changes – evaluation of fatty tissue volume reduction 3. Tolerance of the aspiration method by adolescents (to be measured with AspireAssist patient satisfaction survey) 4. Changes in food intake and dietary habits (to be measured with AspireAssist patient satisfaction survey) 5. Quality of life improvement assessed by means of IWQOL and SF-36. These are all evaluated at 3, 6 and 12 months.

Countries

Czech Republic

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026